Trusted Resource for Clinical Trials, Protocols & Progress
In blinded or double-blinded clinical trials, maintaining the integrity of the blinding is crucial to ensure scientific validity. Any unauthorized access to treatment allocation, unblinded safety data, or randomization information can compromise the trial outcomes and lead to regulatory repercussions.
Click to read the full article.
As clinical trials expand globally and adopt decentralized models, managing user access dynamically becomes critical. Unlike static permissions configured at study startup, dynamic access provisioning allows for:
Click to read the full article.
The principle of Least Privilege (PoLP) mandates that users should only have the minimum access rights necessary to perform their assigned tasks. In the context of clinical trials, this applies to platforms such as:
Click to read the full article.
In clinical research, every interaction with trial data must be traceable. Whether it’s entering patient data, reviewing a protocol amendment, or exporting a dataset, these actions must be logged securely. This is where access logs become critical—they are not just technical records but regulatory evidence.
Click to read the full article.
Electronic Data Capture (EDC) and electronic Trial Master File (eTMF) platforms are the backbone of digital clinical trials. Both require tightly controlled user permissions to ensure data integrity, confidentiality, and traceability. Misconfigured access can result in audit findings, data breaches, or protocol deviations.
Click to read the full article.
Electronic Data Capture (EDC) and electronic Trial Master File (eTMF) platforms are the backbone of digital clinical trials. Both require tightly controlled user permissions to ensure data integrity, confidentiality, and traceability. Misconfigured access can result in audit findings, data breaches, or protocol deviations.
Click to read the full article.
Role-Based Access Control (RBAC) is a widely adopted mechanism for managing user permissions in clinical trial platforms. It ensures that users can only access data and features necessary for their specific roles—an essential requirement under GxP, HIPAA, and GDPR standards.
Click to read the full article.
In 2023, a mid-sized European sponsor initiated a Phase III decentralized clinical trial (DCT) for a dermatological therapy involving 1,800 patients across 6 countries. The study utilized wearable skin imaging devices, home-based ePRO (electronic Patient-Reported Outcomes), and a cloud-hosted CTMS to manage operations.
Click to read the full article.
Quantum computing is no longer a theoretical concept. With breakthroughs in quantum processors and qubit stability, the possibility of breaking traditional encryption schemes like RSA-2048 and ECC is looming on the horizon. Clinical trial data, rich in personal health information (PHI), proprietary formulations, and intellectual property, is a prime target.
Click to read the full article.
Traditional encryption mechanisms—while foundational to digital data security—face growing limitations in the context of modern, multi-regional clinical trials. The rise of decentralized studies, wearable sensors, and remote monitoring technologies has introduced new data flows that legacy encryption strategies struggle to handle.
Click to read the full article.
